Nanotechnology
in drug delivery systems seem to be very attractive to the commercial markets,
however there are few challenges to be highlighted in the aspects of health
environment and public concern in order to introduce nanomedicine to the
market.
Furthermore, as in health environmental
concerns, the health activism groups, non-government associations and
conservationists are rebelling aggressively and bought criticisms regarding
nanomedicine in health have slows down the progress of researching in
nanomedicine and an obvious and extensive of criticism can also be seen in the
medicinal industry.
Moreover,
in public point of views, introducing this type of new advanced nanotechnology
in drug delivery system would be costly.
In development stages, the capability for companies to raise fund in
public market will be difficult since there is a high uncertainty on such
technology investment which there is a high observable failing rate in the
science and technology field. Thence, it is hard for researchers to begin their
nanomedicine research which researchers would have problem in raising fund to
do the research because nanomedicine research return costs a lot of time and
investors tend to lower their value propositions on nanomedicine.
Written By: Team 3 (Go Yuan Fon)
References:
OECD International Futures Programme 2015.
Opportunities and risks of Nanotechnologies. [Online] Available at: http://www.oecd.org/science/nanosafety/37770473.pdf [Accessed 2 June 2015].
Moradi, M., 2004. Nano-enabled Drug Delivery Systems
Market. The Impact of Nanotechnology in Drug Delivery: Global Developments,
Market Analysis, and Future Prospects. [Online] Available at: http://www.nanotech-now.com/Mike-Moradi/NanoMarkets-Drug-Delivery-122004.pdf. [Accessed 2 June 2015].
